Shots:

• The US FDA grants BT designation to Promacta (eltrombopag) + standard immunosuppressive therapy (SIT) for patients with 1L severe aplastic anemia (SAA)
• The BT designation is based on research conducted at NIH results demonstrated complete response @6mos. (52%) & ORR (85%)
• Promacta (eltrombopag) is a TPO receptor agonist and has received FDA’s & EU’s approval for thrombocytopenia in pediatric patients >1yr with insufficient response to corticosteroids and immunoglobulins

Ref: Novartis | Image: Twitter